000			03622nam a22006377a 4500
001			sulb-eb0023097
003			BD-SySUS
005			20160413122334.0
007			cr nn 008mamaa
008			140528s2013 xxk| s |||| 0|eng d
020			_a9781907673948 _9978-1-907673-94-8
024	7		_a10.1007/978-1-907673-94-8 _2doi
050		4	_aRC254-282
072		7	_aMJCL _2bicssc
072		7	_aMED062000 _2bisacsh
082	0	4	_a616.994 _223
100	1		_aAlvarez, Ricardo H. _eauthor.
245	1	0	_aHandbook of HER2-targeted agents in breast cancer _h[electronic resource] / _cby Ricardo H Alvarez, Javier Cortés, Leticia De Mattos-Arruda, Mary Falzon, Angelica Fasolo, Michael Gandy, Luca Gianni, Nadia Harbeck, Martine Piccart, Stefania Zambelli, Dimitrios Zardavas.
264		1	_aTarporley : _bSpringer Healthcare Ltd. : _bImprint: Springer Healthcare, _c2013.
300			_aXI, 96 p. 13 illus. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_aIntroduction and background biology -- HER2 testing -- HER2-positive breast cancer: adjuvant and neoadjuvant therapy -- HER2-positive metastatic breast cancer: first-line treatment -- HER2-positive metastatic breast cancer: second-line treatment -- Emerging targeted agents for HER2-positive breast cancer.
520			_aBreast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year.  Of these cases, approximately  15–25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes.  However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer  provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.
650		0	_aMedicine.
650		0	_aGeneral practice (Medicine).
650		0	_aInternal medicine.
650		0	_aOncology.
650		0	_aPrimary care (Medicine).
650		0	_aPharmacotherapy.
650	1	4	_aMedicine & Public Health.
650	2	4	_aOncology.
650	2	4	_aPrimary Care Medicine.
650	2	4	_aGeneral Practice / Family Medicine.
650	2	4	_aInternal Medicine.
650	2	4	_aPharmacotherapy.
700	1		_aCortés, Javier. _eauthor.
700	1		_aMattos-Arruda, Leticia De. _eauthor.
700	1		_aFalzon, Mary. _eauthor.
700	1		_aFasolo, Angelica. _eauthor.
700	1		_aGandy, Michael. _eauthor.
700	1		_aGianni, Luca. _eauthor.
700	1		_aHarbeck, Nadia. _eauthor.
700	1		_aPiccart, Martine. _eauthor.
700	1		_aZambelli, Stefania. _eauthor.
700	1		_aZardavas, Dimitrios. _eauthor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9781907673931
856	4	0	_uhttp://dx.doi.org/10.1007/978-1-907673-94-8
912			_aZDB-2-SME
942			_2Dewey Decimal Classification _ceBooks
999			_c45189 _d45189